Relationship between antibody titer than the Incidence of Infection After Complete Dose of COVID-19 Astrazeneca Vaccination Based on Sociodemographics
Abstract
Background: Vaccine is an essential tool to limit the health of the COVID -19 pandemic and one of the vaccines that got permitted to used is AstraZeneca Vaccine. The base of the AstraZeneca is the viral vector vaccine. This vaccine has a more advanced method that uses a modified virus to trigger antibodies to make herd immunity for people. Objective: To found correlation between antibody titer than the incidence of Covid infection after complete dose vaccination base on sociodemographics Method: Observasional prospective Cohort method was use in this study with a convenience sampling design. Inclusion criteria were all Indonesian citizens above 18 years old (n=113) who were vaccinated at UTA 45 Jakarta Vaccine Center with no history of COVID -19 before the vaccination and had filled up the informed consents. Results: there were 43 (38%) respondents infected Covid-19 after vaccinated full dosesConclusion: Base on this study, it was found that there was a correlation between sociodemographics after vaccinated full doses AstraZeneca, gender, age, comorbid, smoking, and drinking than infected Covid -19 (P-value < 0.05)).
Keywords: Astrazeneca vaccine, Antibody titer, COVID-19.
Keywords:
Astrazeneca vaccine, Antibody titer, COVID-19DOI
https://doi.org/10.22270/jddt.v14i3.6462References
Djalante R, Lassa J, Setiamarga D, Sudjatma A, Indrawan M, Haryanto B, et al. Review and analysis of current responses to COVID-19 in Indonesia: Period of January to March 2020. Progress in Disaster Science. 2020 Apr;6:100091. https://doi.org/10.1016/j.pdisas.2020.100091 PMid:34171011 PMCid:PMC7149002
Michael, Ramatillah DL. TREATMENT PROFILE AND SURVIVAL ANALYSIS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) COVID-19 PATIENTS. International Journal of Applied Pharmaceutics. 2022 Apr 1;54-6. https://doi.org/10.22159/ijap.2022.v14s2.44750
Araminda GN, Ramatillah DL. Evaluation Comparison Between Astrazeneca and Moderna Vaccine's Side Effects and Efficacy Among Indonesia Society Based On Sociodemography. International Journal of Applied Pharmaceutics. 2022 Apr 1;37-43. https://doi.org/10.22159/ijap.2022.v14s2.44747
Kementrian Kesehatan Republik Indonesia. Masyarakat Indonesia Sambut Baik Vaksinasi Covid-19 [Internet]. 2021 [cited 2023 Dec 20]. Available from: https://promkes.kemkes.go.id/masyarakat-indonesia-sambut-baik-vaksinasi-covid-19.
Alharbi NK, Al-Tawfiq JA, Alwehaibe A, Alenazi MW, Almasoud A, Algaisi A, et al. Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines. Infect Drug Resist. 2022;15:4127-36. https://doi.org/10.2147/IDR.S362848 PMid:35937784 PMCid:PMC9348632
Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet. 2021 Jul;398(10296):213-22.
Kezia V, Ramatillah DL. Intensive Monitroing of Sinovac Vaccine For Safety And Efficacy Among Indonesian Population. International Journal of Applied Pharmaceutics. 2022 Apr 1;44-8. https://doi.org/10.22159/ijap.2022.v14s2.44748
Raghotham S, Balamuralidhara V, Karuna K. Registration Requirement and Approval Procedure of Vaccines in Saudi Arabia. Res J Pharm Technol. 2019;12(9):4531. https://doi.org/10.5958/0974-360X.2019.00780.7
Sette A, Crotty S. Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines. Immunol Rev. 2022 Sep 22;310(1):27-46. https://doi.org/10.1111/imr.13089 PMid:35733376 PMCid:PMC9349657
Lukas S, Laila Ramatillah D, Aldi Y, Sri Wahyuni F. The Impact of Body Mass Index on the Antibody Titer after Astra Zeneca Vaccination at UTA'45 Vaccine Center. Res J Pharm Technol. 2023 Jun 26;2689-93. https://doi.org/10.52711/0974-360X.2023.00441
Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. The Lancet. 2021 Jan;397(10269):72-4. https://doi.org/10.1016/S0140-6736(20)32623-4 PMid:33306990
World Health Organization. Interim recommendations for the use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac [Internet]. 2021 [cited 2023 Oct 8]. Available from: https://www.who.int/indonesia/news/novel-coronavirus.
Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021 Jul;39(32):4423-8. https://doi.org/10.1016/j.vaccine.2021.05.063 PMid:34210573 PMCid:PMC8142841
Aho Glele LS, Simon E, Bouit C, Serrand M, Filipuzzi L, Astruc K, et al. Association between SARS-Cov-2 infection during pregnancy and adverse pregnancy outcomes: A re-analysis of the data reported by Wei et al. (2021). Infect Dis Now. 2022 May;52(3):123-8. https://doi.org/10.1016/j.idnow.2022.02.009 PMid:35182802 PMCid:PMC8847095
Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020 Mar 27;12(4):372. https://doi.org/10.3390/v12040372 PMid:32230900 PMCid:PMC7232198
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020 Jun 11;582(7811):289-93. https://doi.org/10.1038/s41586-020-2223-y PMid:32272481
Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. New England Journal of Medicine. 2020 Oct 29;383(18):1724-34. https://doi.org/10.1056/NEJMoa2026116 PMid:32871063 PMCid:PMC7494247
Burton DR. Antiviral neutralizing antibodies: from in vitro to in vivo activity. Nat Rev Immunol. 2023 Nov 17;23(11):720-34. https://doi.org/10.1038/s41577-023-00858-w PMid:37069260 PMCid:PMC10108814
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 Jul 17;27(7):1205-11. https://doi.org/10.1038/s41591-021-01377-8 PMid:34002089
Dobaño C, Ramírez-Morros A, Alonso S, Vidal-Alaball J, Ruiz-Olalla G, Vidal M, et al. Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. BMC Med. 2021 Dec 28;19(1):155. https://doi.org/10.1186/s12916-021-02032-2 PMid:34183003 PMCid:PMC8237770
Franco-Luiz APM, Fernandes NMGS, Silva TB de S, Bernardes WP de OS, Westin MR, Santos TG, et al. Longitudinal study of humoral immunity against SARS-CoV-2 of health professionals in Brazil: the impact of booster dose and reinfection on antibody dynamics. Front Immunol. 2023 Jul 14;14. https://doi.org/10.3389/fimmu.2023.1220600 PMid:37520570 PMCid:PMC10376701
World Health Organization. Introduction to Vaccine Safety, AEFI Classification 2021. Available from: https://in.vaccine-safety-training.org/adverse-events-classification.html .
Kleebayoon A, Wiwanitkit V. Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations. Journal of the Formosan Medical Association. 2023 May;122(5):432-3. https://doi.org/10.1016/j.jfma.2022.12.018 PMid:36610888 PMCid:PMC9800810
Garwahusada E, Wirjatmadi B. Correlation of Sex, Smoking Habit, Physical Activity and Hypertension among Office Employee. Media Gizi Indonesia. 2020 Jan 2;15(1):60-5. https://doi.org/10.20473/mgi.v15i1.60-65
Putri RN. HUBUNGAN STATUS MEROKOK, KONSUMSI ALKOHOL, DAN JENIS KELAMIN DENGAN OBESITAS SENTRAL PADA REMAJA USIA 15-18 TAHUN (ANALISIS RISKESDAS 2018). [Semarang]: Universitas Diponegoro. 2021. Available from: https://eprints2.undip.ac.id/id/eprint/4965/
Syahrir M, Sabilu Y, Salma WO. HUBUNGAN MEROKOK DAN KONSUMSI ALKOHOL DENGAN KEJADIAN PENYAKIT HIPERTENSI PADA MASYARAKAT WILAYAH PESISIR. Jurnal Ilmiah Ilmu Keperawatan. 2021;12(3).
Yue Y, Hong L, Guo L, Gao X, Deng J, Huang J, et al. Gender differences in the association between cigarette smoking, alcohol consumption and depressive symptoms: a cross-sectional study among Chinese adolescents. Sci Rep. 2015 Dec 7;5(1):17959. https://doi.org/10.1038/srep17959 PMid:26639938 PMCid:PMC4671152
Cui Y, Zhu Q, Lou C, Gao E, Cheng Y, Zabin LS, et al. Gender differences in cigarette smoking and alcohol drinking among adolescents and young adults in Hanoi, Shanghai, and Taipei. Journal of International Medical Research. 2018 Dec 15;46(12):5257-68. https://doi.org/10.1177/0300060518807292 PMid:30442048 PMCid:PMC6300939
Lukas S, Ramatillah DL, Aldi Y, Wahyuni FS, Gloria F, Michael, et al. Hubungan Sosiodemografi dengan Hasil Klinis Pasien Covid-19 di RSUD Bengkulu. JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X. 2022 Jan 31;14(1):25-31. https://doi.org/10.35617/jfionline.v14i1.59
Dai M, Tao L, Chen Z, Tian Z, Guo X, Allen-Gipson DS, et al. Influence of Cigarettes and Alcohol on the Severity and Death of COVID-19: A Multicenter Retrospective Study in Wuhan, China. Front Physiol. 2020 Dec 9;11. https://doi.org/10.3389/fphys.2020.588553 PMid:33362576 PMCid:PMC7756110
Gaydos J, McNally A, Guo R, Vandivier RW, Simonian PL, Burnham EL. Alcohol abuse and smoking alter inflammatory mediator production by pulmonary and systemic immune cells. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2016 Mar 15;310(6):L507-18. https://doi.org/10.1152/ajplung.00242.2015 PMid:26747782 PMCid:PMC4796259
Haddad C, Bou Malhab S, Sacre H, Salameh P. Smoking and COVID-19: A Scoping Review. Tob Use Insights. 2021 Jan 15;14:1179173X2199461. https://doi.org/10.1177/1179173X21994612 PMid:33642886 PMCid:PMC7890709
Uysal EB, Gümüş S, Bektöre B, Bozkurt H, Gözalan A. Evaluation of antibody response after COVID‐19 vaccination of healthcare workers. J Med Virol. 2022 Mar;94(3):1060-6. https://doi.org/10.1002/jmv.27420 Mid:34704620 PMCid:PMC8661654
Sari IP, Sriwidodo S. Perkembangan Teknologi Terkini dalam Mempercepat Produksi Vaksin COVID-19. Majalah Farmasetika. 2020 Aug 24;5(5):204. https://doi.org/10.24198/mfarmasetika.v5i5.28082
ARNANDA N, RAMATILLAH DL. SYSTEMATIC REVIEW: EVALUATION OF CYTOKINE STORM TREATMENT FROM COVID 19 PATIENT BASE ON CLINICAL TRIAL. International Journal of Applied Pharmaceutics. 2022 Apr 1;5-9. https://doi.org/10.22159/ijap.2022.v14s2.44739
Rodrigues R, Costa de Oliveira S. The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression Levels in Patients with Comorbidities on COVID-19 Severity: A Comprehensive Review. Microorganisms. 2021 Aug 9;9(8):1692. https://doi.org/10.3390/microorganisms9081692 PMid:34442770 PMCid:PMC8398209
Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. European Journal of Clinical Microbiology & Infectious Diseases. 2021 May 3;40(5):905-19. https://doi.org/10.1007/s10096-020-04138-6 PMid:33389262 PMCid:PMC7778857
Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020 Dec 13;24(1):422. https://doi.org/10.1186/s13054-020-03120-0 PMid:32660650 PMCid:PMC7356137
Published
Abstract Display: 452 
PDF Downloads: 469 PDF Downloads: 45 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.